Sentence examples for methodologies are largely from inspiring English sources

Although "privacy by design" (PBD embedding privacy protections into products during design, rather than retroactively uses the term "design" to recognize how technical design choices implement and settle policy, design approaches and methodologies are largely absent from PBD conversations.

Thus results from the two methodologies are largely consistent.

The High Point Strategy, as it has come to be known, was aimed at public drug dealing, not gang violence, but the methodology was largely the same.

The proposed methodology is largely built upon two existing KBE methodologies: CommonKADS and MOKA, which have become popular models for automating engineering processes.

In addition, the specific conditions of this test, including timing of the tests and design of the arena, vary between studies; the consequence of these differences in methodology is largely unknown.

This instrumental configuration minimizes sample manipulation and allows the determination of these compounds without the need for a derivatization step so that the methodology is largely shortened and simplified.

Most existing studies mainly focus on those aspects that are directly related to disaster risks, and choosing a proper optimization methodology is largely treated as a minor issue.

The methodology is largely consistent with the Swiss approach as described above, but remains equally vague with respect to how the vulnerability analysis is carried out, and does not address resilience specifically.

However, the methodology is largely empirical and does not consider the physical mechanism of crack tip deformation, especially the cyclic plasticity, which is believed to control crack growth behaviour in metallic alloys.

This framework and methodology is largely credited to the work and theories developed by Stanford professor, bestselling author and entrepreneur Steve Blank, who mentored Eric Ries.

This methodology was largely a tool to gauge the perceptions of key policy makers and stakeholders who have a vested interest in the state of the pharmaceutical system.